Zealand Pharma A/S (ZLDPF PINK) stock market data APIs
$39.1088
-0.02(-0.1%)
as of March 9, 2026
Try our APIs with
free plan!
Zealand Pharma A/S Financial Data Overview
Price chart is built with
Anychart
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
Prev. Close
39.1088
Open
39.0853
High
39.1351
Low
39.0591
52 wk Range
35.931-101.2925
Market Cap
2 789 M
P/E Ratio
2.8194
Shares Outstanding
70 607 K
Revenue
9 215 M
EPS
-0.8368
Beta
0.417
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Zealand Pharma A/S data using free add-ons & libraries
Get Zealand Pharma A/S Fundamental Data
Zealand Pharma A/S Fundamental data includes:
- Net Revenue: 9 215 M
- EBITDA: 6 927 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-19
- EPS/Forecast: -8.17
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Zealand Pharma A/S News
New
Zealand Pharma to participate in upcoming investor conferences in March 2026
Zealand Pharma Press release – No. 5 / 2026 Zealand Pharma to participate in upcoming investor conferences in March 2026 Copenhagen, Denmark, March 9, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (...
Roche Petrelintide Data Recasts Obesity Opportunity And Pipeline Growth Story
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Roche Holding (SWX:ROG) reported highly positive Phase II r...
Zealand Pharma Weighs Petrelintide Trade Offs As Obesity Program Advances
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Zealand Pharma (CPSE:ZEAL) reported topline Phase 2 data ...
Zealand Pharma CEO Says Most-Tolerable Drugs Will Be Next to Win in Obesity Market
The key to unlocking the value of the market is to come up with drugs patients are willing to stay on, according to Zealand’s Adam Steensberg. Continue Reading
Get Zealand Pharma A/S fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
